Médias

Press Release Aug 29. 2019 13:52 GMT

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Press Release Aug 29. 2019 07:39 GMT

Chr. Hansen gearer op til en bæredygtig fremtid

Den globale bioscience virksomhed udvider og styrker forskning- & udviklingsfaciliteterne i Hørsholm for at imødekomme den stigende efterspørgsel efter naturlige og bæredygtige produkter.

Press Release Aug 29. 2019 07:38 GMT

Chr. Hansen gears up for a sustainable future

Global bioscience company Chr. Hansen to expand and strengthen its research & development facilities north of Copenhagen to meet the increasing demand for natural and sustainable products.

Press Release Aug 28. 2019 07:48 GMT

Endnu en influenzasæson er på trapperne, men ny forskning har afsløret et hemmeligt våben, der kan nedbringe omkostningerne ved influenza-lignende sygdom

En ny sundhedsøkonomisk undersøgelse har påvist, at indtagelsen af probiotika kan bidrage til at reducere omkostningerne forbundet med influenza-lignende sygdom. Alene i USA kan indtagelsen af probiotika nedbringe antallet af sygedage med over 54 millioner dage om året, ifølge undersøgelsen.

Press Release Aug 28. 2019 07:22 GMT

As the dreaded flu-season knocks on our door, a new study reveals a secret weapon to reduce the cost of flu-like sickness

A new health economics study shows that the intake of probiotics can help reduce the cost of flu-like sickness. In the US alone, taking probiotics can reduce the number of sick days by over 54 million days per year, according to the study.